BIIB34:BVMF
Biogen
244,50 BRL
arrow_downward
−0,12%(−0,30) 1 D
19. nov., 16:56:00 GMT-3 · BRL
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for BIIB34 …
Åpne
244,50 BRL
Høy
244,50 BRL
Lav
244,50 BRL
Markedsverdi
36,89 mrd.
Snittvolum
3,00
Volum
0,00
52 u høy
244,80 BRL
52 u lav
147,50 BRL
Utestående aksjer
147,82 mill.
Antall ansatte
8k
Åpne
244,50 BRL
Høy
244,50 BRL
Lav
244,50 BRL
Markedsverdi
36,89 mrd.
Snittvolum
3,00
Volum
0,00
52 u høy
244,80 BRL
52 u lav
147,50 BRL
Utestående aksjer
147,82 mill.
Antall ansatte
8k
Nyhetssaker
Fra nettkilder og nyhetspartnere
ad-hoc-news.de
·
for 18 timer siden
Biogen stock: Lecanemab data show benefit in alpha-synuclein group
Investing.com
·
for 1 døgn siden
Mizuho raises Biogen stock price target on commercial execution outlook
Barchart.com
·
for 1 døgn siden
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Investing.com
·
for 2 døgn siden
H.C. Wainwright reiterates Buy rating on Biogen stock at $270
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Om Biogen
Administrerende direktørChristopher A. Viehbacher
Ansatte7,5k
Grunnlagt1978
HovedkontorCambridge, Massachusetts, USA
SektorHealth Care
Bransje-
Nettstedbiogen.com